ArticlePharmacoEconomics2004
Use and cost of antiretrovirals in France 1995-2000: an analysis based on the Medical Dossier on Human Immunodeficiency (release 2) database.
Article in PharmacoEconomics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 10 citations in OpenAlex.
- Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain.The European journal of health economics : HEPAC : health economics in prevention and care · 2010Article
- The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France.PharmacoEconomics · 2010Article
- Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.PharmacoEconomics · 2010Article
- The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain.BMC health services research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the temporal relationship between the uptake of more aggressive antiretroviral (ARV) therapy and the use and cost of hospital treatment for HIV-infected patients in France from 1995 to 2000 from a hospital perspective.
methodsAnalysis of evolutions in health status (CD4+ cell count, transition to AIDS and mortality) and components of hospital treatment (inpatient hospitalisation, outpatient consultations, day hospital stays and hospital ARV prescriptions) based on a sample of 2203 patients in 30 French hospitals, using data from the French Medical Dossier on Human Immunodeficiency (release 2) database. Health status and healthcare consumption were measured per patient and per semester from 1995 to 2000 inclusive, with unit costs applied to resource data (1999 values). Results were stratified for gravity of illness.
resultsBetween 1995 and 2000, there was an overall improvement in health status for HIV-infected patients. The mortality rate dropped by 82% and the incidence of cases of transition to AIDS fell significantly. Over the same period, the proportion of patients on ARV treatment grew from 69.5% to 97%, with a large rise in the use of polytherapy. The increase was most notable for patients with CD4+ cell counts above 500 cells/mm3, in whom the ARV prescription rate rose from 29% to 96% by 2000. This brought ARV expenditure from Euro 637 per patient per semester in 1995 up to Euro 2042 in 2000, an increase of 220%. Inpatient hospitalisation rates fell by 60% and average length of stay decreased, bringing down total hospital costs (excluding ARVs) from Euro 5179 per patient in the first semester of 1995 to Euro 2314 in 2000 (a 55.5% reduction). Total expenditure per patient per semester therefore fell from Euro 5817 to Euro 4356, a 25% decrease.
conclusionThe wider use of multiple combination ARV therapy in France is temporally related to an improvement in the health status of HIV-infected patients, accompanied by reduced consumption of hospital care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.